Cord blood metabolic markers are strong mediators of the effect of maternal adiposity on fetal growth in pregnancies across the glucose tolerance spectrum: the PANDORA study.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
03 2020
Historique:
received: 02 09 2019
accepted: 23 10 2019
pubmed: 10 1 2020
medline: 2 4 2021
entrez: 10 1 2020
Statut: ppublish

Résumé

We aimed to assess associations between cord blood metabolic markers and fetal overgrowth, and whether cord markers mediated the impact of maternal adiposity on neonatal anthropometric outcomes among children born to Indigenous and Non-Indigenous Australian women with normal glucose tolerance (NGT), gestational diabetes mellitus (GDM) and pregestational type 2 diabetes mellitus. From the Pregnancy and Neonatal Outcomes in Remote Australia (PANDORA) study, an observational cohort of 1135 mother-baby pairs, venous cord blood was available for 645 singleton babies (49% Indigenous Australian) of women with NGT (n = 129), GDM (n = 419) and type 2 diabetes (n = 97). Cord glucose, triacylglycerol, HDL-cholesterol, C-reactive protein (CRP) and C-peptide were measured. Multivariable logistic and linear regression were used to assess the associations between cord blood metabolic markers and the outcomes of birthweight z score, sum of skinfold thickness (SSF), being large for gestational age (LGA) and percentage of body fat. Pathway analysis assessed whether cord markers mediated the associations between maternal and neonatal adiposity. Elevated cord C-peptide was significantly associated with increasing birthweight z score (β 0.57 [95% CI 0.42, 0.71]), SSF (β 0.83 [95% CI 0.41, 1.25]), percentage of body fat (β 1.20 [95% CI 0.69, 1.71]) and risk for LGA [OR 3.14 [95% CI 2.11, 4.68]), after adjusting for age, ethnicity and diabetes type. Cord triacylglycerol was negatively associated with birthweight z score for Indigenous Australian women only. No associations between cord glucose, HDL-cholesterol and CRP >0.3 mg/l (2.9 nmol/l) with neonatal outcomes were observed. C-peptide mediated 18% (95% CI 13, 36) of the association of maternal BMI with LGA and 11% (95% CI 8, 17) of the association with per cent neonatal fat. Cord blood C-peptide is an important mediator of the association between maternal and infant adiposity, across the spectrum of maternal glucose tolerance.

Identifiants

pubmed: 31915893
doi: 10.1007/s00125-019-05079-2
pii: 10.1007/s00125-019-05079-2
doi:

Substances chimiques

Biomarkers 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-507

Subventions

Organisme : National Health and Medical Research Council
ID : #631947
Pays : International

Références

N Engl J Med. 2005 Jun 16;352(24):2477-86
pubmed: 15951574
Acta Endocrinol (Copenh). 1952 Apr;9(4):342-64
pubmed: 13007332
Am J Obstet Gynecol. 1995 Oct;173(4):1176-81
pubmed: 7485315
Diabetologia. 2016 Jun;59(6):1089-94
pubmed: 26995651
Diabetes Care. 2013 Jul;36(7):1941-6
pubmed: 23393209
Placenta. 2018 Apr;64:53-60
pubmed: 29626981
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
Diabetes Care. 2012 Mar;35(3):574-80
pubmed: 22301123
Diabetologia. 2015 May;58(5):937-41
pubmed: 25628236
Am J Obstet Gynecol. 2003 Dec;189(6):1698-704
pubmed: 14710101
BMC Health Serv Res. 2017 Aug 3;17(1):524
pubmed: 28774291
N Engl J Med. 2009 Oct 1;361(14):1339-48
pubmed: 19797280
Diabetes. 2009 Feb;58(2):453-9
pubmed: 19011170
J Clin Endocrinol Metab. 2014 Jan;99(1):240-7
pubmed: 24243635
N Engl J Med. 2008 May 8;358(19):1991-2002
pubmed: 18463375
J Clin Endocrinol Metab. 2001 Feb;86(2):935-8
pubmed: 11158070
BMC Pediatr. 2017 Mar 27;17(1):88
pubmed: 28347278
Med J Aust. 2012 Sep 3;197(5):291-4
pubmed: 22938128
Med J Aust. 1998 Jul 20;169(2):93-7
pubmed: 9700346
J Clin Endocrinol Metab. 2009 Nov;94(11):4284-91
pubmed: 19808847
Diabetes Care. 2006 Jun;29(6):1345-50
pubmed: 16732019
Int J Gynaecol Obstet. 2002 Jul;78(1):69-77
pubmed: 12113977
Paediatr Perinat Epidemiol. 2011 Mar;25(2):150-63
pubmed: 21281328
J Clin Endocrinol Metab. 2010 Dec;95(12):5427-34
pubmed: 20843942
J Matern Fetal Neonatal Med. 2013 Nov;26(17):1682-6
pubmed: 23570252
PLoS One. 2017 Aug 4;12(8):e0179487
pubmed: 28777799
Lancet. 2002 May 11;359(9318):1690-2
pubmed: 12020549
Diabetes Care. 2008 Sep;31(9):1858-63
pubmed: 18606978
Diabet Med. 2011 Sep;28(9):1060-7
pubmed: 21843303
Acta Obstet Gynecol Scand. 2012 Dec;91(12):1469-73
pubmed: 22994407
Atherosclerosis. 2004 Sep;176(1):181-7
pubmed: 15306192
Hypertension. 2018 Jul;72(1):24-43
pubmed: 29899139
Diabetes Care. 2000 Dec;23(12):1855-7
pubmed: 11128370
Diabetes. 2011 Jul;60(7):1849-55
pubmed: 21709280
Eur J Pediatr. 1998 Apr;157(4):321-6
pubmed: 9578970
J Pediatr. 2011 Jun;158(6):941-6
pubmed: 21238981
Pediatr Obes. 2019 Apr;14(4):e12490
pubmed: 30650263
Diabetes Care. 1994 Jul;17(7):640-8
pubmed: 7924772
Diabetes Care. 2005 May;28(5):1260-1
pubmed: 15855607
Int J Epidemiol. 2019 Feb 1;48(1):307-318
pubmed: 30508095
Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):338-41
pubmed: 21982556
Reprod Biol Endocrinol. 2015 Jun 26;13:68
pubmed: 26111704
Int J Epidemiol. 2018 Aug 1;47(4):1045-1046h
pubmed: 29618003
Diabetes Care. 1995 Dec;18(12):1550-6
pubmed: 8722050
PLoS One. 2016 Aug 25;11(8):e0161206
pubmed: 27560495
Curr Diab Rep. 2014 Feb;14(2):461
pubmed: 24395435
BMC Pediatr. 2015 Nov 10;15:175
pubmed: 26555879

Auteurs

I-Lynn Lee (IL)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.

Elizabeth L M Barr (ELM)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.
Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Danielle Longmore (D)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.

Federica Barzi (F)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.

Alex D H Brown (ADH)

South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Faculty of Health and Medical Sciences, the University of Adelaide, Adelaide, SA, Australia.

Christine Connors (C)

Northern Territory Department of Health, Darwin, NT, Australia.

Jacqueline A Boyle (JA)

Monash Centre for Health Research and Implementation, School of Public Health and Preventative Medicine, Monash University, Clayton, VIC, Australia.

Marie Kirkwood (M)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.

Vanya Hampton (V)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia.

Michael Lynch (M)

Pathology Network, Top End Health and Hospital Services, Darwin, NT, Australia.

Zhong X Lu (ZX)

Monash Pathology, Monash Health, Melbourne, VIC, Australia.
Department of Medicine, Monash University, Melbourne, VIC, Australia.

Kerin O'Dea (K)

School of Health Sciences, University of South Australia, Adelaide, SA, Australia.

Jeremy Oats (J)

Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.

H David McIntyre (HD)

Mater Medical Research Institute, University of Queensland, Brisbane, QLD, Australia.

Paul Zimmet (P)

Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Jonathan E Shaw (JE)

Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.

Louise J Maple-Brown (LJ)

Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, 0811, Australia. Louise.Maple-Brown@menzies.edu.au.
Division of Medicine, Royal Darwin Hospital, Darwin, NT, Australia. Louise.Maple-Brown@menzies.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH